<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>葛兰素史克（GSK plc，GSK，GSK.L）宣布，日本卫生、劳动和福利部已扩大 RSV 疫苗 Arexvy 的适用人群，包括 18 至 49 岁有 RSV 疾病高风险的成年人。GSK 的 RSV 疫苗此前已在日本获得批准，用于预防 60 岁及以上所有成年人的 RSV 疾病，以及 50 至 59 岁成年人有 RSV 疾病的适应症。</p>
<p>该公司表示，此次批准得到了 III 期 b 临床试验数据的支持，该试验显示 18 至 49 岁成年人在 RSV 疾病方面的免疫反应与 60 岁及以上成年人相比并不劣于。</p>
<p>GSK 专有的 AS01 佐剂系统包含从 Agenus Inc.的子公司 Antigenics 获得的 STIMULON QS-21 佐剂。</p>
<p>截至上次收盘，GSK plc 的股票交易价格为 1859.50 便士，下跌 0.16%。</p>
<p>欲获取更多健康新闻，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

葛兰素史克

<p>葛兰素史克（GSK plc）宣布，日本厚生劳动省已将其 RSV 疫苗 Arexvy 的适用人群扩大至 18 至 49 岁、面临 RSV 疾病高风险的成年人。这一决定是在之前对老年人群体的批准基础上做出的。该决定得到了 III 期 b 临床试验数据的支持，显示年轻年龄组的免疫反应相当。GSK 的股价收于 1,859.50 便士，下跌 0.16%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>GSK plc (GSK,GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at increased risk for RSV disease. GSK's RSV vaccine was previously approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease.</p>
<div class="lb-trans"><p>葛兰素史克（GSK plc，GSK，GSK.L）宣布，日本卫生、劳动和福利部已扩大 RSV 疫苗 Arexvy 的适用人群，包括 18 至 49 岁有 RSV 疾病高风险的成年人。GSK 的 RSV 疫苗此前已在日本获得批准，用于预防 60 岁及以上所有成年人的 RSV 疾病，以及 50 至 59 岁成年人有 RSV 疾病的适应症。</p>
</div><p>The company said the approval was supported by data from a Phase IIIb trial demonstrating a non-inferior immune response in adults aged 18 to 49 years AIR for RSV disease compared to adults aged 60 years and above.</p>
<div class="lb-trans"><p>该公司表示，此次批准得到了 III 期 b 临床试验数据的支持，该试验显示 18 至 49 岁成年人在 RSV 疾病方面的免疫反应与 60 岁及以上成年人相比并不劣于。</p>
</div><p>The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics, a subsidiary of Agenus Inc.</p>
<div class="lb-trans"><p>GSK 专有的 AS01 佐剂系统包含从 Agenus Inc.的子公司 Antigenics 获得的 STIMULON QS-21 佐剂。</p>
</div><p>At last close, GSK plc shares were trading at 1,859.50 pence, down 0.16%.</p>
<div class="lb-trans"><p>截至上次收盘，GSK plc 的股票交易价格为 1859.50 便士，下跌 0.16%。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲获取更多健康新闻，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

GSK: Japan's MHLW Expands Eligible Population For Arexvy

葛兰素史克：日本厚生劳动省扩大了 Arexvy 疫苗的适用人群范围